Why the study?
Does adjunctive tirofiban therapy improve reperfusion, LVEF, and clinical outcomes in patients with acute STEMI undergoing primary PCI?
Does adjunctive tirofiban therapy improve reperfusion, LVEF, and clinical outcomes in patients with acute STEMI undergoing primary PCI?
Adjunctive tirofiban during primary PCI for STEMI significantly improves angiographic reperfusion, ST-segment resolution, and LVEF without increasing bleeding complications, though it did not significantly reduce 30-day MACE.
Tirofiban adjunct to STEMI PCI was associated with greater ST resolution; leaves open effects on clinical outcomes in modern practice.
Background: The introduction of stents and the use of platelet glycoprotein IIb/IIIa inhibitors, either alone or in combination with reduced-dose fibrinolytic therapy, has allowed percutaneous coronary intervention (PCI) to be performed more safely and synergistically following pharmacologic reperfusion therapy. Aims and Objectives: The present study was conducted to evaluate the efficacy and safety of tirofiban as an adjunct to angioplasty/stenting in acute ST-elevation myocardial infarction (MI) patients. Materials and Methods: A total of 156 consecutive patients diagnosed with acute ST-segment elevation MI (STEMI) presenting within 12 h of symptoms were randomly allocated to primary PCI alone or primary PCI along with tirofiban. Clinical characteristics, angiographic findings (including thrombolysis in MI [TIMI] flow rate), and ST-segment resolution were compared post-procedurally; left ventricular ejection fraction (LVEF) and major adverse cardiac events (MACE, including death, reinfarction, and target vessel revascularization) were compared at 30 days clinical follow-up. Results: Post-procedurally, TIMI Grade 3 reflow was significantly different between two groups (P = 0.01) and was associated with better in-hospital outcomes in tirofiban group compared with control group. Greater resolution of ST-elevation was achieved in patients given tirofiban than in non-tirofiban group, and the results were highly significant. Statistically significant improvement in LVEF was also observed in tirofiban group. There was non-significant difference in MACE and bleeding complications between two groups. Conclusion: Adjunctive tirofiban therapy for patients with acute STEMI, who underwent primary PCI, seems to be safe and effective treatment modality to achieve improved reperfusion, better LVEF, and clinical outcome at 30 days follow-up. [Natl J Physiol Pharm Pharmacol 2016; 6(6.000): 531-536]
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: